Leqembi for early Alzheimer's treatment launched in India after CDSCO nod
Eisai launched Leqembi (lecanemab) in India for early Alzheimer's treatment after receiving marketing authorization from the Central Drugs Standard Control Organisation (CDSCO). This marks the introduction of India's first disease-modifying therapy for early Alzheimer's, addressing a growing dementia burden that affects 8.8 million Indians aged 60 and above. Eisai emphasized the importance of early intervention and plans to implement patient support programs to enhance accessibility and affordability.